Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Jun 4 - Jun 8, 2021The 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 11 - May 14, 202124th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Apr 10 - Apr 15, 2021AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) 2021 ANNUAL MEETING